Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment.
The efficacy and safety of a new diuretic-antihypertensive drug, indapamide (2.5 mg/day), were evaluated in hypertensive patients with normal renal function, in patients with various degrees of chronic renal failure, and in hypertensive patients undergoing long-term maintenance hemodialysis. The results obtained from single-blind, placebo-controlled studies indicate that indapamide is a safe and effective agent to use in lowering the blood pressure of hypertensive patients with normal renal function, those with various degrees of renal impairment, and those who are undergoing long-term maintenance hemodialysis. No significant side or toxic effects were noted in these studies. Furthermore, indapamide does not accumulate in the bloodstream of patients with renal impairment and is not dialyzable.
D000450:Aldosterone / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004232:Diuretics / Q000009:adverse effects*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007190:Indapamide / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications*; D007677:Kidney Function Tests; D007700:Kinetics; D006435:Renal Dialysis; D012083:Renin / Q000097:blood
D004232:Diuretics; D000450:Aldosterone; D012083:Renin; D007190:Indapamide